Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS-1167 + Bevacizumab in Recurrent Ovarian Cancer
NCT06308406Phase 2Recruiting
- Sponsor
- Hengrui
- Start
- Mar 2024
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of M9466 in ovarian cancer, sponsored by Hengrui. Primary endpoints: Dose-Limiting Toxicity at 21 days and Recommended Phase II Dose at 21 days. Started Mar 2024; status: recruiting.
02
Drugs
M9466
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT06308406.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06308406.